OTLK Stock Summary and Trading Ideas (Outlook Therapeutics | NASDAQ:OTLK)

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.

As of April 26, 2024, OTLK stock price climbed to $8.43 with 119,571 million shares trading.

OTLK has a beta of -2.62, meaning it tends to be less sensitive to market movements. OTLK has a correlation of 0.03 to the broad based SPY ETF.

OTLK has a market cap of $196.41 million. This is considered a Micro Cap stock.

In the last 3 years, OTLK stock traded as high as $65.40 and as low as $4.00.

The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

OTLK has underperformed the market in the last year with a price return of -61.3% while the SPY ETF gained +26.8%. OTLK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.1% and -6.7%, respectively, while the SPY returned +4.5% and -1.9%, respectively.

OTLK support price is $7.55 and resistance is $8.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK stock will trade within this expected range on the day.